Scholar Rock Holding Corporation was incorporated in Delaware in May 2012. The company is a biopharmaceutical company focused on the discovery and development of innovative drugs for the treatment of serious diseases in which protein growth factor signaling plays an important role. As a global leader in transforming growth factor β superfamily biology, the company's new understanding of the molecular mechanism of growth factor activation enables it to develop a proprietary platform for the discovery and development of locally and selectively targeted growth factor precursors or potential forms of monoclonal antibodies. Based on this proprietary and scalable technology platform, the company is building a growing portfolio of novel product candidates designed to transform the lives of patients with multiple serious diseases, including neuromuscular diseases, cancer, fibrosis and iron-limiting anemia. 

Expected P&L on Expiry

Key Stats

Pricing Model

About SRRK20260918C60